Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (IMPACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00806234|
Recruitment Status : Completed
First Posted : December 10, 2008
Results First Posted : April 25, 2017
Last Update Posted : April 25, 2017
|Condition or disease||Intervention/treatment||Phase|
|Psychotic Disorders||Drug: Aripiprazole or Perphenazine Drug: Metformin Drug: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine||Phase 4|
Disorders that involve severe dysregulation of mood or thoughts in children -- such as early onset bipolar spectrum (BPS) and schizophrenia spectrum (SS) disorders -- are commonly treated with antipsychotic medications. However, many of the newest and most commonly prescribed antipsychotic medications can cause weight gain and metabolic dysfunctions. Use of these newer antipsychotics, called second generation antipsychotics (SGAs), is increasing rapidly in children, and the risk of weight gain from SGAs is higher among children than adults. Excessive weight gain can lead to obesity, which, in turn, can lead to increased health care costs, increased risk of sickness, and lower life expectancy. These factors are enhanced in children and adolescents who grow up obese.
Two different strategies to reduce weight gain and metabolic side effects from SGAs will be tested in this study. The first strategy involves switching from the current SGA to a lower risk agent (aripiprazole or perphenazine) hypothesized to result in weight loss and improved metabolic functioning. The second strategy involves taking the medication metformin in addition to the current SGA. Metformin is approved by the Food and Drug Administration (FDA) to promote weight loss in youth with diabetes and has been effective in reducing weight in youth taking SGAs.
Participation in this study will last between 26 and 27 weeks and will be divided into two parts. The first part will last 2 to 3 weeks and include three study visits. During this part, participants will undergo a physical exam, an electrocardiogram (EKG), a dual energy X-ray absorptiometry (DXA) test, and blood tests. The DXA measures body fat.
The second part will last 24 weeks and include nine study visits. During this part, participants will be randomly assigned to one of three conditions: gradual switch of current SGA medication to either aripiprazole or perphenazine, addition of metformin to current SGA medication, or no change to treatment with current SGA medication. Visits will take place on Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24. At each visit, participants will meet with a study doctor who will assess symptoms and side effects, and participants and their guardians will receive information and recommendations about childhood obesity and weight loss. There will also be monthly urine pregnancy tests, and two blood tests.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||127 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||March 2014|
|Actual Study Completion Date :||March 2014|
Active Comparator: 1
Participants will continue on current antipsychotic medication.
Drug: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
Other Name: Zyprexa, Seroquel, Risperdal, Geodon, Abilify, Saphris, Sycrest, Fanapt, Fanapta, Zomaril, Latuda, Invega, Symbyax
Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.
Drug: Aripiprazole or Perphenazine
Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
Other Name: Abilify, Trilafon
Participants will add metformin to current antipsychotic medication treatment.
Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
Other Name: Glucophage
- Body Mass Index (BMI) Z-score Change [ Time Frame: Change from baseline to 24 weeks ]
- Change in Whole Body Insulin Sensitivity Index [ Time Frame: Change from baseline to 24 weeks ]
- Triglyceride Levels [ Time Frame: Change from baseline to 24 weeks ]
- Change in Low Density Lipoprotein (LDL) Cholesterol Level [ Time Frame: From Baseline to Week 24 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00806234
|United States, Maryland|
|University of Maryland|
|Baltimore, Maryland, United States, 21201|
|Johns Hopkins Hospital|
|Baltimore, Maryland, United States, 21205|
|United States, New York|
|The Zucker Hillside Hospital|
|Glen Oaks, New York, United States, 11004|
|United States, North Carolina|
|University of North Carolina, Division of Child and Adolescent Psychiatry|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Gloria Reeves, MD||University of Maryland, College Park|
|Principal Investigator:||Linmarie Sikich, MD||University of North Carolina, Division of Child and Adolescent Psychiatry|
|Principal Investigator:||Christoph Correll, MD||The Zucker Hillside Hospital|
|Principal Investigator:||Mark A. Riddle, MD||Johns Hopkins University|